Laura Quan Man Chow, MD, FRCPC, director of the Thoracic, Head and Neck Cancer and Clinical Immunotherapy Programs, associate cancer center director for Clinical Research, The University of Texas at Austin, discusses the use of ceritinib (Zykadia) in patients with 

-positive non—small cell lung cancer that has metastasized to the brain. 

-positive NSCLC improves, so does the likelihood of developing leptomeningeal disease, says Chow. According to the results of the phase II ASCEND-7 trial, the use of ceritinib was effective in controlling leptomeningeal metastasis in patients with 

The trial sets the standard for measuring the activity of targeted agents in this setting, she adds. Moreover, the study shows proof-of-concept that targeted therapy may be more effective than radiation for patients with these driver mutations.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ESMO Congress

Laura Quan Man Chow, MD, FRCPC, discusses the use of ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer that has metastasized to the brain. 

Dr. Chow on the Use of Ceritinib in ALK+ NSCLC Metastatic to the Brain